Dihydroartemisinin-Piperaquine for the Chemoprevention of Malaria in Children with Sickle Cell Anaemia in eastern and southern Africa

Start and End dates: 2019 to 2023

Source of Funding: Norwegian Research Council ($1.8million)

This is an individual double-blind randomized clinical trial assessing the efficacy and safety of malaria chemoprevention with dihydroartemisinin-piperaquine compared to sulfadoxine-pyrimethamine in children with sickle cell anaemia. We are recruiting 548 children aged between 6 months and 15 years in Malawi and Uganda and following them up for 18 months.